BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9306417)

  • 21. [Prostate-specific antigen].
    Eide IA; Angelsen A
    Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2528-31. PubMed ID: 11070990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical significance of prostate specific antigen (PSA) and PSA density in the detection of T1a and T1b prostate cancer].
    Meguro N; Maeda O; Saiki S; Kinouchi T; Kuroda M; Usami M; Kotake T
    Hinyokika Kiyo; 1998 Sep; 44(9):639-43. PubMed ID: 9805668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel diagnostic test for prostate cancer emerges from the determination of alpha-methylacyl-coenzyme a racemase in prostatic secretions.
    Zielie PJ; Mobley JA; Ebb RG; Jiang Z; Blute RD; Ho SM
    J Urol; 2004 Sep; 172(3):1130-3. PubMed ID: 15311056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beyond PSA: utility of novel tumor markers in the setting of elevated PSA.
    Lin DW
    Urol Oncol; 2009; 27(3):315-21. PubMed ID: 19414121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)].
    Tsuchiya N; Ohyama C; Habuchi T
    Gan To Kagaku Ryoho; 2005 Feb; 32(2):275-80. PubMed ID: 15751649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PSA and other tissue kallikreins for prostate cancer detection.
    Stephan C; Jung K; Lein M; Diamandis EP
    Eur J Cancer; 2007 Sep; 43(13):1918-26. PubMed ID: 17689069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
    Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
    Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between prostate size and percent free prostate-specific antigen in patients with operable prostate cancer.
    Nativ O; Sabo E; Wald M; Halachmi S; Moskovitz B
    Isr Med Assoc J; 2000 Dec; 2(12):889-91. PubMed ID: 11344767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prostate-specific antigen and its related parameters in detecting prostate cancer].
    Kuruma H; Egawa S
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):11-5. PubMed ID: 12557698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of prostate-specific antigen in the evaluation of benign prostatic hyperplasia.
    Tchetgen MB; Oesterling JE
    Urol Clin North Am; 1995 May; 22(2):333-44. PubMed ID: 7539179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
    Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
    Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes.
    Xu J; Meyers DA; Sterling DA; Zheng SL; Catalona WJ; Cramer SD; Bleecker ER; Ohar J
    Cancer Epidemiol Biomarkers Prev; 2002 Jul; 11(7):664-9. PubMed ID: 12101115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The search for better markers for prostate cancer than prostate-specific antigen].
    Schenk-Braat EA; Bangma CH
    Ned Tijdschr Geneeskd; 2006 Jun; 150(23):1286-90. PubMed ID: 16821452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Free and total human glandular kallikrein 2 in patients with prostate cancer.
    Väisänen V; Pettersson K; Alanen K; Viitanen T; Nurmi M
    Urology; 2006 Jul; 68(1):219-25. PubMed ID: 16844459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The current role of prostatic acid phosphatase and prostate-specific antigen in the management of prostate cancer.
    Shetty SD; Cerny JC
    Henry Ford Hosp Med J; 1992; 40(1-2):93-8. PubMed ID: 1385363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues.
    Olsson AY; Bjartell A; Lilja H; Lundwall A
    Int J Cancer; 2005 Jan; 113(2):290-7. PubMed ID: 15389512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients.
    Ylikoski A; Karp M; Pettersson K; Lilja H; Lövgren T
    J Mol Diagn; 2001 Aug; 3(3):111-22. PubMed ID: 11486050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate-specific antigen: update 1997.
    Chan DW; Sokoll LJ
    J Int Fed Clin Chem; 1997 Sep; 9(3):120-5. PubMed ID: 10174623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The PSA gene: value in detection of circulating prostate cancer cells].
    de la Taille A; Colombel M; Amsellem S; Muscatelli B; Radvanyi F; Mazeman E; Abbou CC; Chopin D
    Prog Urol; 1997 Dec; 7(6):930-6. PubMed ID: 9490137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostatic specific antigen.
    el-Shirbiny AM
    Adv Clin Chem; 1994; 31():99-133. PubMed ID: 7533474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.